Skip to main content
  • Facebook
  • Twitter
  • Linkedin
Menu  

Main navigation

  • Home
  • Journal
    • Current Issue
    • Archive
    • Subscribe
      • Begin Print Subscription 
      • Renew Print Subscription 
    • For Authors
      • Author Guidelines
      • Submit a Manuscript 
    • For Advertisers
    • About the Journal
      • Editorial Information
      • Editorial Advisory Board
      • Journal Staff 
      • Contact
  • Topics
    • Latest News
    • Research & Insight
    • Columns
    • Interviews
    • Centers of Excellence
      • Multiple Myeloma
    • Conference Coverage
    • Special Reports
    • FDA Approvals
    • Guidelines Updates
    • Health Economics and Outcomes Research
    • Policy Updates
    • Precision Medicine
    • Real-World Outcomes
    • Value-Based Care
  • Treatment Areas
    • Autoimmune Diseases
    • Blood Cancer
    • Breast Cancer
    • CAR-T Therapies
    • Cardiovascular Diseases
    • Colorectal Cancer
    • Diabetes
    • Gastrointestinal Cancer
    • Head & Neck Cancer
    • Hematologic Malignancies
    • Immuno-Oncology
    • Leukemia & Lymphoma
    • Lung Cancer
    • Multiple Myeloma
    • Non-Small Cell Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Sarcoma
    • Supportive Care
  • Multimedia
    • Interactive Feature: Multiple Myeloma
    • Podcasts
    • Slideshows
    • Videos
  • CME
    • NACCME CME
    • Partner CME
  • Meeting
  • Login
  • Subscription
  • E-Newsletter
Submitted by admin on Thu, 05/04/2017 - 09:57

Imlygic® (talimogene laherparepvec injection), per 1 million plaque forming units

Resource Center
Skin Cancer
Resource Section
J Code Updates
URL
https://www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.ht…
Brand
Journal Of Clinical Pathways

Latest News

April 26, 2018
Clinical, Cost Implications of HER2+ Breast Cancer in the New Era of Value-Based Care
April 26, 2018
Diagnosis-to-Treatment Interval Associated With Prognostic Factors in DLBCL
April 25, 2018
Real-World Study Determines Effectiveness of Targeted Therapy for Relapsed, Refractory B-Cell Malignancy
More News

E-News

Get the lastest JCP updates straight to your email!

Sign up!

Slideshow

News and Research Highlights in CLL, ALL, and AML
blood
SEE MORE SLIDESHOWS >

jcp

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. © 2017 HMP Communications

© 2018 HMP Communications ®

  • About
  • Contact Us
  • Privacy Statement

Connect with the JCP Family

  • cpc
  • oncology
  • jcp